MRKR News and Press, Marker Therapeutics Inc. From 12/29/23

2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...

HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that ...

2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...

2023-12-11 16:53:07 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Marker Therapeutics, Inc. (NASDAQ: MRKR), Poseida Therapeutics (NASDAQ: PSTX), Assure Holdings (NASDAQ: IONM), Jet AI (NASDAQ: JTAI), and NextPlay Techn...

2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...

2023-12-11 12:16:39 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Pasithea Therapeutics Corp (NASDAQ: KTTA), Marker Therapeutics Inc (NASDAQ: MRKR), Macy’s Inc (...

HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical ...

2023-11-10 11:12:12 ET More on Marker Therapeutics Marker gains as lymphoma therapy leads to complete remission Financial information for Marker Therapeutics For further details see: Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M

Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 ( zedenoleucel ) for t...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...